Biosimilars Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Oncology, Inflammatory and Autoimmune Diseases, Chronic Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, and Others), By Product (Monoclonal Antibodies, Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationBiosimilars Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Oncology, Inflammatory and Autoimmune Diseases, Chronic Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, and Others), By Product (Monoclonal Antibodies, Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, F
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 29.52 Billion |
| CAGR (2024-2029) | 5.25% |
| Fastest Growing Segment | Oncology |
| Largest Market | North America |
| Market Size (2029) | USD 40.22 Billion |
Market Overview
Global Biosimilars Market w
Many blockbuster biologic drugs have faced or are set to face patent expirations, allowing biosimilar manufacturers to enter the market. This creates a competitive landscape and paves the way for more affordable options for patients.
Key Market Drivers
Increasing Prevalence of Chronic Diseases is Driving the Global Biosimilars Market
The global biosimilars market is witnessing a significant surge in growth, and one of the primary driving forces behind this expansion is the increasing incidence of chronic diseases worldwide. Chronic diseases, such as cancer, diabetes, and autoimmune disorders, have become a growing global health concern, leading to a higher demand for effective and affordable treatment options. Biosimilars, which are biological drugs highly similar to their reference biologic products, offer a promising solution to address the economic and healthcare challenges posed by chronic diseases
Biosimilars are biological drugs designed to be highly similar to already approved reference biologics, which are complex molecules derived from living organisms. Unlike generic drugs, which are chemically identical to their brand-name counterparts, biosimilars are structurally similar but not identical. To gain approval, biosimilars must demonstrate comparable quality, safety, and efficacy to their reference products. The biosimilars market has been on the rise due to its potential to provide cost-effective alternatives to expensive biologic therapies. Biologics are typically used to treat chronic diseases, such as rheumatoid arthritis, cancer, and diabetes. They have significantly improved patient outcomes but come with a hefty price tag. Biosimilars can offer cost savings while maintaining therapeutic effectiveness.
Chronic diseases, also known as non-communicable diseases (NCDs), are long-lasting conditions that can often be managed but not cured. They include conditions like cardiovascular diseases, cancer, diabetes, and autoimmune disorders. Chronic diseases have become a global epidemic, and their incidence is steadily increasing due to various factors such as aging populations, sedentary lifestyles, and poor dietary choices.
Growing Aging Population is Driving the Global Biosimilars Market
According to the United Nations, by 2050, nearly 1 in 6 people globally will be over the age of 65, compared to 1 in 11 in 2019
As people age, the likelihood of developing chronic and complex medical conditions increases. These conditions often require long-term and expensive treatments, including biologics. Biologics are advanced drugs made from living organisms and have revolutionized the treatment of various diseases, such as cancer, autoimmune disorders, and diabetes. However, their high cost is a major barrier to access for many patients. This is where biosimilars come into play. Biosimilars are highly similar to their reference biologics and provide an opportunity to reduce healthcare costs without compromising on efficacy and safety. They offer a more affordable option for the aging population, making these life-saving treatments more accessible.
Biosimilars can reduce the financial burden on healthcare systems, insurers, and patients. For an aging population that often requires multiple medications and treatments, cost savings can significantly improve healthcare accessibility.
Key Market Challenges
Regulatory Hurdles
One of the primary challenges facing the biosimilars market is navigating the complex and evolving regulatory landscape. Developing biosimilars requires demonstrating similarity to an originator biologic, which can be a daunting task. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established rigorous guidelines for biosimilar approval. This demands extensive clinical trials and thorough analytical studies, making the development process time-consuming and expensive. Harmonizing these regulations across different regions remains an ongoing challenge, as each market has its own set of requirements.
Intellectual Property Issues
Intellectual property rights surrounding biologics and biosimilars have been a source of contention. Original biologic manufacturers often hold numerous patents, which can make it difficult for biosimilar manufacturers to access and analyze reference products. This leads to delayed market entry and costly legal battles over patent infringement. While some regulatory provisions exist to expedite biosimilar entry, the delicate balance between protecting innovation and promoting competition remains a significant challenge.
Manufacturing Complexity
The production of biosimilars is inherently complex. These drugs are composed of large, intricate molecules, and even minor differences in the manufacturing process can affect product quality and efficacy. Biosimilar manufacturers must establish robust and consistent manufacturing processes to ensure their products are highly similar to the reference biologic. Achieving this level of consistency requires significant investment in research and development, as well as state-of-the-art manufacturing facilities.
Market Competition
Market Access and Adoption
Even with regulatory approval, achieving market access for biosimilars can be challenging. Many healthcare systems are slow to adopt biosimilars due to concerns about product safety and efficacy, lack of familiarity, or hesitancy to switch from reference products. Educational efforts, economic incentives, and collaboration among stakeholders are required to overcome these barriers.
Physician and Patient Acceptance
Physicians play a pivotal role in the adoption of biosimilars. They need to be confident in the efficacy and safety of biosimilars and comfortable with prescribing them. Patients, too, may have reservations about switching from a trusted reference product to a biosimilar, fearing a loss of therapeutic benefit. Effective communication and education are essential to address these concerns.
Variability of Biological Response
Biological variability is a fundamental challenge in the biosimilars market. Unlike small molecule drugs, biologics can trigger different responses in different individuals. Variability in patient responses to biosimilars and reference biologics adds complexity to clinical trials and requires extensive post-market monitoring.
Key Market Trends
Technological Advancements
The global biosimilars market has been witnessing remarkable growth in recent years, driven by the convergence of two powerful forcesrising technological advancements and the increasing demand for cost-effective biologic therapies. Biosimilars, also known as follow-on biologics, are biologic products that are highly similar to reference biologics, with no clinically meaningful differences in terms of quality, safety, and efficacy. These biosimilar medicines have become a critical component of healthcare ecosystems around the world, offering a viable solution to the soaring costs of innovative biologics
One of the primary challenges in developing biosimilars is ensuring that they are highly similar to the reference biologics in terms of structure and function. Advanced analytical techniques, such as mass spectrometry, nuclear magnetic resonance, and high-performance liquid chromatography, have made it possible to thoroughly characterize the structure and properties of biologic drugs. This has greatly facilitated the development and approval of biosimilars by enabling manufacturers to demonstrate the structural similarity required for regulatory approval.
Developing efficient and cost-effective manufacturing processes is another key aspect of biosimilar development. Advances in bioprocessing technologies, such as single-use bioreactors and continuous manufacturing, have significantly reduced production costs and increased the scalability of biosimilar manufacturing. This, in turn, has made biosimilars more competitive in terms of pricing. Regulatory authorities around the world have established clear guidelines for the approval of biosimilars, which have evolved alongside technological advancements. These guidelines provide a clear framework for demonstrating bio similarity and ensuring patient safety. The development of regulatory pathways specific to biosimilars has accelerated the approval process, allowing biosimilar manufacturers to bring their products to market more efficiently.
Segmental Insights
Indication Insights
Based
Product Insights
The monoclonal antibodies segment is projected to experience rapid growth during the forecast period. Monoclonal antibodies are a type of biologic drug designed to mimic the body's natural immune response. They are engineered to target specific proteins or receptors in the body, making them highly effective in treating a variety of medical conditions, including cancer, autoimmune disorders, and infectious diseases. Due to their precision and effectiveness, mAbs have gained immense popularity in the field of medicine. Monoclonal antibodies are used to treat a wide array of diseases, including cancer, autoimmune disorders, and infectious diseases. This versatility has contributed to their increasing demand in the biosimilars market. As more therapeutic areas are explored, the scope for mAb biosimilars continues to expand. The primary motivation behind the development and adoption of biosimilars is to reduce the economic burden of biologic therapies. Monoclonal antibody biosimilars offer significant cost savings to both healthcare systems and patients, making them a preferred choice for many.
Regional Insights
North America emerged as the dominant player in the global Biosimilars market in 2023, holding the largest market share in terms of value. Regulatory bodies in North America, including the U.S. Food and Drug Administration (FDA) and Health Canada, have created clear pathways for the approval and commercialization of biosimilars. Their guidelines and robust approval processes have fostered a competitive environment, attracting both local and international pharmaceutical companies to invest in biosimilar development. North America boasts a well-established pharmaceutical industry with deep pockets and extensive research capabilities. This infrastructure provides a solid foundation for research and development, enabling companies to engage in biosimilar development projects.
Recent Developments
- In January 2023, Amgen Inc. introduced AMJEVITA(adalimumab-atto), a biosimilar for Humira (adalimumab), within the UnitedStates. AMJEVITA (40 mg) is offered at a wholesale acquisition cost that is 55% lower than the current list price of Humira. Additionally, AMJEVITA is available at a price 5% lower than that of Humira. Amgen aims to ensure widespread patient access by providing two pricing options to health plans and pharmacy benefit managers.
Key Market Players
- Dr. Reddy's Laboratories Ltd.
- Sandoz Group AG
- Coherus Biosciences
- Viatris Inc.
- Bio-Thera Solutions
- Pfizer Inc.
- Apobiologix
- Teva Pharmaceuticals
- Biocon Ltd
- Reliance Life Sciences
| By Indication | By Product | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy